Scott Ahlstrom
Medical · Kenilworth, ILNPI 1538628938
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. Among medical clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$751
- Kaleo, Inc.$531
- Sanofi$528
- Genentech USA, Inc.$381
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,99997%
- Education$1913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $1,932 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,160 |
| GSK | 37 | $751 |
| Kaleo, Inc. | 25 | $531 |
| Sanofi | 22 | $528 |
| Genentech USA, Inc. | 17 | $381 |
| Novartis | 17 | $251 |
| Pharming Healthcare, Inc. | 8 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $173 |
| Hikma Pharmaceuticals USA | 7 | $140 |
| Blueprint Medicines Corporation | 5 | $126 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $110 |
| Teva Pharmaceuticals USA, Inc. | 5 | $103 |
| Pfizer | 4 | $99 |
| Biocryst US Sales Co., LLC | 4 | $90 |
| Covis Pharma GmbH | 4 | $88 |
| Boehringer Ingelheim | 4 | $84 |
| Phadia US Inc. | 4 | $75 |
| AbbVie | 3 | $69 |
| Optinose US, Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Alk-abello, Inc | 2 | $41 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Amgen | 2 | $34 |
| Cycle Pharmaceuticals Inc | 1 | $31 |
How this compares
$7,190 in reported general payments places this provider in the 90th percentile of 449 medical providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,426 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,451 |
| Ipratropium Bromide | 14 | $335 |
| Montelukast Sodium | 19 | $309 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $263 |
| Prednisone | 29 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $751 | $12,42612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 449 medical providers in Illinois.
Other medical in Kenilworth
- Andrea TurekChicago$145K
- Priya BediElmhurst$56K
- Jennifer GarsonChicago$32K
- Bernice JohnsonPalos Heights$32K
- William KvasnickaChicago$19K
- Katie SpringerLake Forest$17K
- Matthew BrunoMorris$17K
- Kelly BrawleyBarrington$14K
- Megan GriggsSpringfield$13K
- Marianne RaoAlgonquin$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.